Additionally, our findings in BRAF-mutant CRC showed that MSI-stable patients were more likely to receive chemotherapy (OR = 7.226) but experienced worse survival than their MSI-unstable counterparts (p = 0.00001), consistent with prior literature linking MSI status to immunogenicity and treatment response. Here, BRAF is linked to colorectal carcinoma.